EU wholesalers express concern with pharma package

- Last updated on GMT

Related tags: Member states, European union

The European Association of Pharmaceutical Full-line Wholesalers (GIRP) says it has concerns about the anti-counterfeiting proposals contained in the European Commission's recently-released 'pharmaceutical package.'

The GIRP welcomed the EC's proposal for new legislation aimed at preventing the entry of medicinal products which are "falsified in view of identity, history or source​" into the legal supply chain.

However, the wholesale group takes issue with what it describes as "the lack of initiative to properly tackle a number of important issues associated with the distribution chain.​"

Specifically, the GIRP is concerned about the number of licenses issued to distributors across the EU.

"Despite the widespread problem regarding the number of distribution licenses throughout the member states, ranging to over a 1,000 in some countries, no attempt is made to clean up or harmonise the conditions under which member states grant new licenses or control existing ones​," it claims.

It also takes issue with the fact that there are no provisions for mandatory inspections of “all license holders and all other actors in the supply chain.​"

One solution could be to include a ‘sunset clause’ applicable to all licenses, which would cause a license to expire "should it not be used over a defined time period.​"

The GIRP also believes the EC has missed an opportunity to establish a database of the existence or status of all wholesale players, other than Good Distribution Practices-compliant distributors and Good Manufacturing Practice-compliant manufacturers.

"The Commission acknowledges that, 'in order to ensure reliability in the distribution chain, pharmaceutical legislation should address actors in the distribution chain, but surprisingly neglects to address this point in their proposed amendments.​"

Instead, the EC's strategy of keeping counterfeit medicines out of the legitimate supply chains of member states rests on what the trade body dismisses as "a rather inconsequential national notification procedure.​"

The Commission acknowledges the distribution chain has become very complex, and is only as strong as its weakest link​,” said the GIRP.

“[But] it overlooks the day-to-day consequences of not making clear cut distinctions laying out defined responsibilities between the various players.​"

Regrettably, the Commission has invested a great deal of energy on issues which will yield little impact for addressing the ‘weakest link’. This means ‘other players’ will largely remain unaccountable,​” it concludes.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us

Products

View more

Webinars